COMBINATION OF FACTOR VII AND AN ANTI-FACTOR IX/X BISPECIFIC ANTIBODY
The invention concerns a combination comprising transgenic factor VII and a multispecific antibody directed against factor IX and X, for simultaneous or separate administration.
1 . Pharmaceutical composition comprising:
a. transgenic factor VII, and
b. a multispecific antibody directed against factor IX and factor X,
2 . Pharmaceutical composition according to claim 1 , wherein said transgenic factor VII is a human factor VII derived from production by epithelial cells of the mammary glands of a transgenic non-human mammal.
3 . Pharmaceutical composition according to claim 2 , wherein said transgenic mammal is a rabbit.
4 . Pharmaceutical composition according to any one of claims 1 to 3 , wherein the antibody is emicizumab.
5 . Combination product comprising:
a. transgenic factor VII, and
b. a multispecific antibody directed against factor IX and factor X,
for its use in preventing or treating a coagulation disorder in a patient.
6 . Combination product according to claim 5 , in the treatment of hemophilia A.
7 . Combination product according to one of claim 5 or 6 in the treatment of hemophilia A with factor VIII inhibitors.
8 . Combination product for its use according to claims 5 to 7 , said combination product being in the form of a pharmaceutical composition such as defined in any one of claims 1 to 4 .
9 . Combination product for its use according to claims 5 to 8 , said factor Vila and said antibody being in a form suited to simultaneous administration to the patient.
10 . Combination product for its use according to claims 5 to 8 , said factor Vila and said antibody being in forms suited to separate administration to the patient.
11 . Kit comprising
A container containing transgenic factor FVII; and
Another container containing an antibody directed against factor IX and factor X.
12 . Method to treat a coagulation disorder in a patient, which method comprises the simultaneous or sequential administration to said patient of transgenic factor VII and a multispecific antibody directed against factor IX and factor X.
13 . Use of a combination of transgenic factor VII and a multispecific antibody directed against factor IX and factor X for the treatment of a coagulation disorder in a patient, preferably hemophilia A, with factor VIII inhibitors.